Johns Hopkins spinout WindMIL grabs $32.5M to fuel its work on a next-gen approach to cell therapy
New approaches to personalized cancer cell therapies are in no shortage these days. But execs at WindMIL Therapeutics, which has just closed a $32.5 million Series B round, believe they have something “truly differentiated.”
The Baltimore-based startup is tapping memory T cells residing in the bone marrow — and their innate ability to recognize tumors — to make what they call a novel class of cancer therapy. Founded out of the labs of Johns Hopkins University professors Ivan Borrello and Kim Noonan, WindMIL got its name, in part, from the result of reactivating and expanding these memory T cells extracted from the patient’s body: marrow infiltrating lymphocytes, or MILs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.